SAB BIOTHERAPEUTICS, INC. Current Liabilities
SAB BIOTHERAPEUTICS, INC. (SABS) had Current Liabilities of $11.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $11.71M.
- 2026-03-31: Liabilities, Current $9.85M.
- 2025-12-31: Liabilities, Current $10.68M; Liabilities, Current as first filed $10.68M.
- 2025-09-30: Liabilities, Current $10.79M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $11.71M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $9.85M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $10.68M 10-Q · filed 2026-08-06 | $10.68M 10-K · filed 2026-03-09 |
| 2025-09-30 | $10.79M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $10.68M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $9.65M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $7.98M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $8.82M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $7.55M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $8.30M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $10.81M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $9.21M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $11.01M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $13.67M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $14.99M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $17.10M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $16.39M 10-K · filed 2023-04-14 | $16.14M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $19.27M 10-K · filed 2023-04-14 | $18.26M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $26.46M 10-K/A · filed 2023-04-28 | $24.68M 10-K · filed 2022-03-29 |
| 2021-09-30 | $322.38K 10-Q · filed 2021-11-22 | |
| 2021-06-30 | $152.88K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $80.00K 10-Q · filed 2021-05-21 | |
| 2021-01-14 | $267.54K 10-Q · filed 2021-08-09 | |
| 2020-12-31 | $11.06M 10-K/A · filed 2023-04-28 | $306.20K 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |